GeneDx Holdings Corp. WGS

WGS Company Overview

GeneDx Holdings Corp. is a genomics and diagnostics company focused on applying whole genome sequencing and advanced bioinformatics to improve the diagnosis and management of rare and complex genetic conditions. The company operates within the clinical diagnostics, genomics, and precision medicine industries, serving healthcare providers, hospitals, life sciences companies, and researchers. Its core offering centers on high-resolution genetic testing intended to shorten diagnostic timelines and improve clinical decision-making.

The company’s primary revenue is generated through clinical genetic testing services, with a particular emphasis on pediatric and rare disease diagnostics, including neurology, cardiology, and metabolic disorders. GeneDx Holdings Corp. traces its origins to GeneDx, founded in 2000 as a spin-out from the National Institutes of Health. The business was acquired by OPKO Health, Inc. in 2012, later sold to Sema4 in 2021, and subsequently emerged as an independent public company in 2023 under the name GeneDx Holdings Corp., refocusing the organization exclusively on clinical genomics after divesting other Sema4 operations.